The DOI matches its Crossref record; 259 of the 260 references it cites were found in a registry or an index.
Biomarkers in Neurodegenerative Diseases
Abstract
The past decade has seen tremendous efforts in biomarker discovery and validation for neurodegenerative diseases. The source and type of biomarkers has continued to grow for central nervous system diseases, from biofluid-based biomarkers (blood or cerebrospinal fluid (CSF)), to nucleic acids, tissue, and imaging. While DNA remains a predominant biomarker used to identify familial forms of neurodegenerative diseases, various types of RNA have more recently been linked to familial and sporadic forms of neurodegenerative diseases during the past few years. Imaging approaches continue to evolve and are making major contributions to target engagement and early diagnostic biomarkers. Incorporation of biomarkers into drug development and clinical trials for neurodegenerative diseases promises to aid in the development and demonstration of target engagement and drug efficacy for neurologic disorders. This review will focus on recent advancements in developing biomarkers for clinical utility in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this study, patients with severe schizophrenia, receiving Cognitive Remediation Therapy (CRT), were differentiated from control participants with less severe schizophrenia (no CRT recommended) by non-verbal speech analysis.”
From A Review of Automated Speech and Language Features for Assessment of Cognitive and Thought Disorders (2020) · cites this paper as [39]
In the citing paper
“Additionally, nonverbal speech cues, e.g. counting the number of interruptions, interjections, natural turns, and response times can also indicate identifying features of irregular speech patterns [39].”
From A Review of Automated Speech and Language Features for Assessment of Cognitive and Thought Disorders (2020) · cites this paper as [39]
In the citing paper
“Automated acoustic metrics can be extracted from non-labeled speech samples [35], [39], [38], [102].”
From A Review of Automated Speech and Language Features for Assessment of Cognitive and Thought Disorders (2020) · cites this paper as [39]
In the citing paper
“Preliminary results from this study with participants with severe schizophrenia (n = 8) and less-severe forms of the disease (n = 7) indicate that these nonverbal cues show approximately 90% accuracy in classifying control participants from those with more severe forms of schizophrenia.”
From A Review of Automated Speech and Language Features for Assessment of Cognitive and Thought Disorders (2020) · cites this paper as [39]
In the citing paper
“Most interestingly, changes in the outward flow of speech may precede measurable language-based changes [39], [42].”
From A Review of Automated Speech and Language Features for Assessment of Cognitive and Thought Disorders (2020) · cites this paper as [39]
Citations
Cites
Items 201–259 of 259
Saresella, M., Piancone, F., Tortorella, P., Marventano, I., Gatti, A. V., Caputo, D., Lunetta, C., Corbo, M., Rovaris, M., & Clerici, M. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.010 · Cited by 84
Blood Biomarkers for Amyotrophic Lateral Sclerosis: Myth or Reality?
Robelin, L., & de Aguilar, J. G. (2014) · BioMed Research International · doi:10.1155/2014/525097 · Cited by 83
Schuster, C., Kasper, E., Machts, J., Bittner, D., Kaufmann, J., Benecke, R., Teipel, S. J., Vielhaber, S., & Prudlo, J. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7083-z · Cited by 82
Genome-Wide Analysis of the Heritability of Amyotrophic Lateral Sclerosis
Keller, M. F., Ferrucci, L., Singleton, A., Tienari, P. J., Laaksovirta, H., Restagno, G., Chiò, A., Traynor, B. J., & Nalls, M. A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1184 · Cited by 82
DiFrancesco, J. C., Longoni, M., & Piazza, F. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00207 · Cited by 80
Lister‐James, J., Pontecorvo, M. J., Clark, C. M., Joshi, A. D., Mintun, M. A., Zhang, W., Lim, N. C., Zhuang, Z., Golding, G., Choi, S., et al. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.03.001 · Cited by 79
Chen, Z., & Ma, L. (2010) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2010.516265 · Cited by 79
Spreading of amyotrophic lateral sclerosis lesions--multifocal hits and local propagation?
SEKIGUCHI, T., Kanouchi, T., Shibuya, K., Noto, Y., Yagi, Y., Inaba, A., Abe, K., Misawa, S., Orimo, S., Kobayashi, T., et al. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305617 · Cited by 78
pNfH is a promising biomarker for ALS
Ganesalingam, J., An, J., Bowser, R. P., Andersen, P. M., & Shaw, C. E. (2012) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2012.729596 · Cited by 77
Self-citationCSF glial markers correlate with survival in amyotrophic lateral sclerosis
Süßmuth, S. D., Sperfeld, A. D., Hinz, A. V., Brettschneider, J., Endruhn, S., Ludolph, A., & Tumani, H. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d5dc3b · Cited by 76
da Costa, A. L. C., Peppe, A., Carlesimo, G. A., Zabberoni, S., Scalici, F., Caltagirone, C., & Angelucci, F. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00253 · Cited by 75
Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease
Godau, J., Herfurth, M., Kattner, B., Gasser, T., & Berg, D. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.175752 · Cited by 73
Review: The genetics of A lzheimer's disease; putting flesh on the bones
Medway, C., & Morgan, K. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12101 · Cited by 72
Lehnert, S., Costa, J., de Carvalho, M. A., Kirby, J., Kuźma‐Kozakiewicz, M., Morelli, C., Robberecht, W., Shaw, P. J., Silani, V., Steinacker, P., et al. (2014) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.884592 · Cited by 72
Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies
Kantarci, K., Yang, C., Schneider, J. A., Senjem, M. L., Reyes, D. A., Lowe, V. J., Barnes, L. L., Aggarwal, N. T., Bennett, D. A., Smith, G. E., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.007 · Cited by 72
Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers
Helmich, R. C. G., Thaler, A., van Nuenen, B. F. L., Gurevich, T., Mirelman, A., Marder, K. S., Bressman, S., Orr‐Urtreger, A., Giladi, N., Bloem, B. R., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001189 · Cited by 72
Positron emission tomography radioligands for in vivo imaging of Aβ plaques
Mason, N. S., Mathis, C. A., & Klunk, W. E. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2989 · Cited by 68
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 68
The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study.
Seifert, K. D., & Wiener, J. I. (2013) · Europe PMC (PubMed Central) · Cited by 66
Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue
Lemoine, L., Saint‐Aubert, L., Marutle, A., Antoni, G., Eriksson, J., Ghetti, B. F., Okamura, N., Nennesmo, I., Gillberg, P.-G., & Nordberg, A. K. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0220-4 · Cited by 65
Comparison of New Tau PET-Tracer Candidates With [ 18 F]T808 and [ 18 F]T807
Declercq, L., Celen, S., Lecina, J., Ahamed, M., Tousseyn, T., Moechars, D., Alcázar, J., Ariza, M., Fierens, K., Bottelbergs, A., et al. (2016) · Molecular Imaging · doi:10.1177/1536012115624920 · Cited by 63
Ziebell, M., Khalid, U., Klein, A. B., Aznar, S., Thomsen, G., Jensen, P., & Knudsen, G. M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.010 · Cited by 62
Clinical Genetics of Alzheimer’s Disease
Zou, Z., Liu, C., Che, C., & Huang, H. (2014) · BioMed Research International · doi:10.1155/2014/291862 · Cited by 60
Heurling, K., Leuzy, A., Zimmer, E. R., Lubberink, M., & Nordberg, A. K. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3208-1 · Cited by 59
Biomarker-Based Predictive Models for Prognosis in Amyotrophic Lateral Sclerosis
Su, X., Simmons, Z., Mitchell, R. M., Kong, L., Stephens, H., & Connor, J. R. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4646 · Cited by 59
Li, J., Sung, M., & Rutkove, S. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065976 · Cited by 59
Protein biomarkers for amyotrophic lateral sclerosis
Ryberg, H., & Bowser, R. P. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.249 · Cited by 59
Self-citationTetsuka, S., Morita, M., Ikeguchi, K., & Nakano, I. (2013) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.11 · Cited by 58
Lu, C., Petzold, A., Kalmár, B., Dick, J. R. T., Malaspina, A., & Greensmith, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040998 · Cited by 56
Picillo, M., Erro, R., Santangelo, G., Pivonello, R., Longo, K., Pivonello, C., Vitale, C., Amboni, M., Moccia, M., Colao, A., et al. (2013) · Journal of Neurology · doi:10.1007/s00415-013-6851-0 · Cited by 56
Antibody drugs for Alzheimer’s show glimmers of promise
Reardon, S. (2015) · Nature · doi:10.1038/nature.2015.18031 · Cited by 55
Multimodal MRI as a diagnostic biomarker for amyotrophic lateral sclerosis
Foerster, B. R., Carlos, R. C., Dwamena, B. A., Callaghan, B. C., Petrou, M., Edden, R. A. E., Mohamed, M. A., Welsh, R. C., Barker, P. B., Feldman, E. L., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.30 · Cited by 55
Bozik, M. E., Mitsumoto, H., Brooks, B. R., Rudnicki, S. A., Moore, D. H., Zhang, B., Ludolph, A., Cudkowicz, M., van den Berg, L. H., Mather, J. L., et al. (2014) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.943672 · Cited by 53
Ngo, S. T., Baumann, F., Ridall, P., Pettitt, A. N., Henderson, R. D., Bellingham, M. C., & McCombe, P. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2012.01.028 · Cited by 52
Shefner, J. M., Cudkowicz, M., & Brown, R. H. (2006) · Muscle & Nerve · doi:10.1002/mus.20628 · Cited by 52
Pellecchia, M. T., Santangelo, G., Picillo, M., Pivonello, R., Longo, K., Pivonello, C., Vitale, C., Amboni, M., Rosa, A. D., Moccia, M., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12137 · Cited by 51
Wang, L. L., Spieker, A. J., Li, J., & Rutkove, S. B. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.04.021 · Cited by 51
Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis
Turner, M. R., Hammers, A., Allsop, J. M., Al‐Chalabi, A., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Andersen, P. M. (2007) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960701538734 · Cited by 48
Genetics of dementia: Update and guidelines for the clinician
Cohn‐Hokke, P. E., Elting, M. W., Pijnenburg, Y. A. L., & Swieten, J. C. V. (2012) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32080 · Cited by 47
Distinct patterns of cortical atrophy in ALS patients with or without dementia: An MRI VBM study
Rajagopalan, V., & Pioro, E. P. (2014) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.880179 · Cited by 44
Molecular mechanisms of long ncRNAs in neurological disorders
Vučićević, D., Schrewe, H., & Ørom, U. A. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00048 · Cited by 40
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function
Shi, M. Y., Furay, A. R., Sossi, V., Aasly, J. O., Armaly, J., Wang, Y., Wszołek, Z. K., Uitti, R. J., Hasegawa, K., Yokoyama, T., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.015 · Cited by 39
Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir
Trembath, L., Newell, M., & Devous, M. D. (2015) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.115.156679 · Cited by 39
Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers
Vilas, D., Ispierto, L., Álvarez, R., Pont‐Sunyer, C., Martı́, M. J., Valldeoriola, F., Compta, Y., de Fàbregues, O., Hernández‐Vara, J., Puente, V., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.08.007 · Cited by 38
Amyotrophic lateral sclerosis: Is the spinal fluid pathway involved in seeding and spread?
Smith, R. A., Myers, K. J., Ravits, J., & Bowser, R. P. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.07.014 · Cited by 34
Self-citationAn exploratory study of serum creatinine levels in patients with amyotrophic lateral sclerosis
Chen, X., Guo, X., Huang, R., Zheng, Z., Chen, Y., & Shang, H. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1807-4 · Cited by 33
(123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study
Siepel, F. J., Rongve, A., Buter, T. C. E., Beyer, M. K., Ballard, C. G., Booij, J., & Aarsland, D. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002642 · Cited by 33
Kami, K., Morikawa, Y., Kawai, Y., & Senba, E. (1999) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199911)22:11 · Cited by 28
Rajagopalan, V., Yue, G. H., & Pioro, E. P. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7012-1 · Cited by 28
Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer’s Disease
Giil, L. M., Kristoffersen, E. K., Vedeler, C. A., Aarsland, D., Nordrehaug, J. E., Winblad, B. G., Cedazo-Mı́nguez, Á., Lund, A., & Reksten, T. R. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150053 · Cited by 28
Electrical impedance myography as a biomarker for ALS
Rutkove, S. B. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70030-4 · Cited by 26
VOGT, T. M., Kramer, K., Gartenschläger, M., & Schreckenberger, M. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.04.002 · Cited by 25
Koval, L., Lykhmus, O., Kalashnyk, O., Bachinskaya, N. Y., Kravtsova, G., Soldatkina, M. A., Zouridakis, M., Stergiou, C., Tzartos, S. J., Tsetlin, V. I., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101845 · Cited by 24
Wang, H., Golob, E. J., Bert, A., Nie, K., Chu, Y., Dick, M. B., Mandelkern, M. A., & Su, M. (2008) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988708328212 · Cited by 24
Induction of autoantibodies to glutamate in patients with Alzheimer’s disease
Davydova, T. V., Voskresenskaya, N. I., Fomina, V. G., Vetrilé, L. A., & Doronina, O. A. (2007) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-007-0044-8 · Cited by 21
Ahn, S.-W., Kim, S.-H., Oh, D.-H., Kim, S., Park, K. S., Hong, Y., Kwon, O.-S., Sung, J., & Lee, K. W. (2010) · Journal of Korean Medical Science · doi:10.3346/jkms.2010.25.9.1359 · Cited by 16
Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS
Quinn, C. C., Macklin, E. A., Atassi, N., Bowser, R. P., Boylan, K., Cudkowicz, M., Fournier, C. N., Ladha, S. S., Lacomis, D., & Berry, J. D. (2013) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2013.808227 · Cited by 8
Self-citationThe Correlation between Uric Acid Levels and Amyotrophic Lateral Sclerosis
Lin, Y., Lin, T., & Lai, M.-L. (2013) · American journal of clinical medicine research · doi:10.12691/ajcmr-1-3-1 · Cited by 3
Price (1999) · doi:10.1002/1531-8249(199903)45:3
Flagged first, then by citations
1 of the 260 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bézard, E., Pastores, G., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 566
Molecular mechanisms of ischemia and glutamate excitotoxicity
Neves, D., Salazar, I. L., Almeida, R. D., & Silva, R. M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121814 · Cited by 233
Rastogi, S., Sharma, V., Bharti, P. S., Rani, K., Modi, G. P., Nikolajeff, F. K., & Kumar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010440 · Cited by 176
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases
Khalaf, K., Tornese, P., Cocco, A., & Albanese, A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00307-z · Cited by 156
Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 152
Metadata
- Authors
- Jeromin, A., & Bowser, R.
- Affiliations
- Barrow Neurological Institute (US)
- Corresponding author
- Bowser, Robert
- ORCID
- Bowser, Robert
- Venue
- Advances in Neurobiology
- Publisher
- Springer International Publishing
- Published
- 2017
- Volume
- 15
- Pages
- 491-528
- ISSN
- 2190-5215 (ISSN-L)
- 2190-5223
- OpenAlex
- W2733688271
- Cited by
- 92
- References
- 260
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 11 · 2023: 20 · 2022: 16 · 2021: 13 · 2020: 5 · 2019: 7 · 2018: 8
- FWCI
- 17.51
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Advances in neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (RC1NS068179, NS068179, NS061867)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- biomarkers, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cerebrospinal fluid biomarkers, blood biomarkers, RNA biomarkers, DNA biomarkers, neuroimaging biomarkers, familial neurodegenerative disease, drug development, clinical trials, target engagement
- MeSH terms
- Alzheimer Disease, Amyotrophic Lateral Sclerosis, Brain, DNA, Humans, Parkinson Disease, Prognosis, RNA, Biomarkers, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
